Medipost Co Ltd
Medipost Co Ltd is a South Korean biotechnology company focused on healthcare diagnostics and related research, primarily generating revenue through the development and commercialization of diagnostic products and services.
Business. Medipost Co Ltd (078160.KQ) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Medipost Co Ltd (078160.KQ) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.19, indicating a conservative leverage profile. With a current ratio of 1.33, Medipost maintains sufficient short-term liquidity to cover its obligations. The company's price-to-book ratio of 2.06 suggests that the market values the company at a premium to its book value, while the price-to-tangible-book ratio is identical, indicating no significant intangible asset premium.
Profitability metrics reveal a challenging operating environment. The company reported a net loss of KRW 85.4 billion and an operating loss of KRW 83.2 billion in the latest period, resulting in a negative return on equity of -34.29% and a return on assets of -19.79%. These figures are well below the industry median for profitability, indicating a need for operational improvements or strategic shifts to restore earnings.
Geographically, Medipost's revenue is concentrated in South Korea, with no disclosed international segments. The company's business is entirely within the healthcare diagnostics segment, with no diversification across product lines or geographic regions. This concentration increases exposure to domestic regulatory and economic shifts.
Growth prospects appear muted in the near term. The company's revenue of KRW 73.7 billion in the latest period shows no clear upward trajectory, and the outlook for the current and next fiscal years does not indicate significant revenue growth. The company's operating cash flow is negative at KRW -57.1 billion, and free cash flow is also negative at KRW -83.3 billion, suggesting a reliance on external financing or asset sales to fund operations.
Risk factors include the company's negative net income and operating income, which raise concerns about long-term sustainability. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and operating losses suggest a potential need for future capital raising, which could lead to dilution.
Recent filings and transcripts do not highlight any major strategic shifts or new product launches. The company's financial performance remains a key focus area, with no significant events reported in the latest disclosures that would suggest a turnaround in operations.
- Medipost operates in the healthcare diagnostics segment with a conservative capital structure and low leverage.
- The company is currently unprofitable, with negative returns on equity and assets, and no clear path to profitability.
- Revenue is concentrated in South Korea, with no international diversification or segmental breakdown.
- Growth prospects are limited, with negative operating and free cash flows indicating a need for external financing.
- Risk factors include operational losses and potential future dilution, though no immediate liquidity or dilution flags are present.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Medipost Co Ltd Market data — financials · 2026-05-26